APA (7th ed.) Citation

Witte, T., Sogkas, G., Dubrowinskaja, N., Atschekzei, F., Graalmann, T., Fedchenko, M., . . . Ringshausen, F. C. (2023, October). Rituximab to treat prolidase deficiency due to a novel pathogenic copy number variation in PEPD. RMD Open.

Chicago Style (17th ed.) Citation

Witte, Torsten, Georgios Sogkas, Natalia Dubrowinskaja, Faranaz Atschekzei, Theresa Graalmann, Mykola Fedchenko, Abdulwahab Elsayed, and Felix C. Ringshausen. "Rituximab to Treat Prolidase Deficiency Due to a Novel Pathogenic Copy Number Variation in PEPD." RMD Open Oct. 2023.

MLA (9th ed.) Citation

Witte, Torsten, et al. "Rituximab to Treat Prolidase Deficiency Due to a Novel Pathogenic Copy Number Variation in PEPD." RMD Open, Oct. 2023.